AGAmardeep S. Grewal

Amardeep S. Grewal

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Amardeep S. Grewal has a total of 34 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Accuracy of ChatGPT‐4 Plus in Providing Information on Oral Cancer Management

    by Busra Yilmaz, Emine Nur Kahraman, Michael T. Brennan, Amardeep S. Grewal, Aynur Aktas

    Objective: Artificial intelligence (AI)‐driven large language models, such as Chat Generative Pre‐Trained Transformer (ChatGPT)‐4 Plus, are increasingly used for patient education and clinical decision support in oral oncology, although their accuracy in oral cancer (OC) management remains uncertain. This study evaluates the accuracy of ChatGPT‐4 Plus responses to clinically relevant questions regarding OC diagnosis, treatment, recovery, and prevention. Methods: A cross‐sectional study assessed 65 clinically relevant OC‐related questions using a paid ChatGPT‐4 Plus subscription without modifications. Three oral medicine specialists and one radiation oncologist rated accuracy on a four‐point scoring system. Interrater reliability was measured with the intraclass correlation coefficient (ICC), and chi‐square tests were used for comparisons. Results: Among 65 questions, 63% of responses were Score 1, with none rated as Score 4. Score 1 was most frequent in Recovery (72%), followed by Treatment (62%), Prevention (60%), and Diagnosis (55%). Scores 2 and 3 responses were highest in Diagnosis (45%). Recovery had significantly higher Score 1 responses than Diagnosis ( p < 0.05), while other comparisons were not significant. ICC ranged from 0.85 to 0.93. Conclusions: ChatGPT‐4 Plus provided accurate responses to clinically relevant OC‐related questions, particularly regarding recovery. However, diagnostic inconsistencies highlight the need for clinician oversight before integrating AI into practice.


  • Tumor bed proton irradiation in young children with localized medulloblastoma

    by Amardeep S. Grewal, Yimei Li, Michael J. Fisher, Jane Minturn, Iris Paltin, Jean Belasco, Peter Phillips, Tammy Kang, Robert A. Lustig, Christine Hill‐Kayser

    Background: Radiotherapy is often deferred in very young children with medulloblastoma, in favor of more intense chemotherapy and stem cell rescue; however, posterior fossa radiation has been shown to improve overall survival (OS) and event‐free survival compared with adjuvant chemotherapy alone. This study was performed to assess the OS, recurrence‐free survival (RFS), patterns of failure, and clinical toxicity for children aged five and under who received focal proton radiation to the tumor bed alone.Procedure: From 2010 to 2017, 14 patients with newly diagnosed medulloblastoma at one institution received tumor bed irradiation following surgery and chemotherapy. The median age of the patients was 40 months (range, 10.9‐62.9 months).Results: With a median follow‐up of 54 months, four patients relapsed: three within the central nervous system (CNS) outside of the posterior fossa, and one within the tumor bed after subtotal resection. All relapses occurred within 28 months after the completion of radiation therapy. Five‐year OS and RFS for this cohort of patients were 84% (95% CI, 48%‐96%) and 70% (95% CI, 38%‐88%), respectively. One patient experienced significant tumor regrowth soon after completion of radiation, autopsy showed viable tumor and necrosis near and within the brainstem, with relation to radiation unknown; however, no other acute clinical toxicities greater than grade 2 were observed in this group of patients. In the nine patients with available performance status follow‐up, no significant changes in Lansky performance status were observed.Conclusions: Five‐year OS and RFS following tumor bed irradiation in young children with medulloblastoma appear to be improved compared with other studies that forego the use of radiation therapy in this patient population. This approach should be further investigated in young children with medulloblastoma.


  • Open Access

    Role of Metastatic Site Irradiation in Pediatric Patients with Metastatic Ewing Sarcoma

    by A.S. Grewal, Y. Li, S.K. Grewal, R. Bagatell, N. Balamuth, R.B. Womer, G. Kurtz, C.E. Hill-Kayser

  • Pharyngeal‐sparing radiation for head and neck carcinoma of unknown primary following TORS assisted work‐up

    by Amardeep S. Grewal, Karthik Rajasekaran, Steven B. Cannady, Ara A. Chalian, Alireza F. Ghiam, Alexander Lin, Virginia LiVolsi, John N. Lukens, Nandita Mitra, Kathleen T. Montone, et al.

    Objective: In patients with head and neck carcinoma of unknown primary (HNCUP;pT0) following TORS‐assisted workup, we have adopted a pharyngeal‐sparing radiation therapy (PSRT) approach targeting only the at‐risk neck and omitting treatment of the pharynx. We report outcomes following PSRT, and compare to institutional historical control subjects who received pharyngeal‐targeted RT (PRT).Methods: Between 2009 and 2018, 172 patients underwent TORS‐assisted endoscopy as part of their workup for HNCUP. Following TORS, 54 patients had pT0 disease, of which 45 received RT. Forty‐nine percent received PSRT and 51% received PRT.Results: No statistically significant differences existed between the PSRT and PRT groups with respect to overall nodal distribution, p16 positivity (55% vs. 43%, P = .12), neck dissection rates (77% vs. 65%, P = .51), and administration of chemotherapy (55% vs. 65%, P = .55). Median follow‐up for PSRT and PRT groups were 24 and 28 months, respectively (P = .04). Two‐year RFS was 86% and 74% for PSRT and PRT patients, respectively (log‐rank P = .30). Three and six patients recurred after PSRT and PRT, respectively. Two‐year OS for PSRT and PRT patients was 91% and 74%, respectively (log‐rank P = .31). Compared to PRT, PSRT was associated with statistically significantly less: grade 2+ mucositis (18% vs. 91%, P < .01), new opioid requirement (27% vs. 91%, P < .01), mean weight loss during RT (6.2 lbs vs. 17.4 lbs, P < .01), feeding tube placement during RT (5% vs. 43%, P < .01), and treatment‐related unplanned hospitalizations (9% vs. 39%, P = .04).Conclusion: Following TORS‐assisted management of patients with pT0 HNCUP, we observed reduced toxicity following PSRT compared to PRT without apparent compromise of disease cure.Level of Evidence: Level 3 evidence, retrospective review comparing cases and controlsLaryngoscope, 130:691–697, 2020